Drug class
Acyclic nucleotide phosphonate prodrug; antiretroviral reverse-transcriptase inhibitor precursor
Mechanism of action
Tenofovir disoproxil is a prodrug that is hydrolysed to tenofovir and subsequently phosphorylated intracellularly to tenofovir diphosphate. Tenofovir diphosphate competitively inhibits HIV reverse transcriptase and HBV DNA polymerase and causes DNA-chain termination. Fumarate is the salt component; the disoproxil moiety is the prodrug.
General use cases
- Treatment of HIV-1 infection in combination with other antiretroviral agents
- Treatment of chronic hepatitis B in adults and adolescents where authorised; use requires current product-specific eligibility, renal assessment and monitoring
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
